These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30001848)

  • 41. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
    Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.
    Lievens C; Berdy G; Douglass D; Montaquila S; Lin H; Simmons P; Carlisle-Wilcox C; Vehige J; Haque S
    Cont Lens Anterior Eye; 2019 Aug; 42(4):443-449. PubMed ID: 30573298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection.
    Van Daele DJ; Finnegan EM; Rodnitzky RL; Zhen W; McCulloch TM; Hoffman HT
    Arch Otolaryngol Head Neck Surg; 2002 Aug; 128(8):956-9. PubMed ID: 12162778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Botulinum toxin-A-induced protective ptosis in the treatment of lagophthalmos associated with facial paralysis.
    Yücel OE; Artürk N
    Ophthalmic Plast Reconstr Surg; 2012; 28(4):256-60. PubMed ID: 22785583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Botulinum A toxin treatment in patients with oromandibular dystonia with concomitant malnutrition].
    Budrewicz S; Koszewicz M; Góral M
    Neurol Neurochir Pol; 2003; 37 Suppl 5():55-60. PubMed ID: 15098332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beneficial effects of botulinum toxin type A in trigeminal neuralgia.
    Zúñiga C; Díaz S; Piedimonte F; Micheli F
    Arq Neuropsiquiatr; 2008 Sep; 66(3A):500-3. PubMed ID: 18813708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cosmetic indications for botulinum A toxin.
    Foster JA; Wulc AE; Holck DE
    Semin Ophthalmol; 1998 Sep; 13(3):142-8. PubMed ID: 9787215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uses of botulinum toxin.
    Girdler NM
    Lancet; 1997 Mar; 349(9056):953. PubMed ID: 9093271
    [No Abstract]   [Full Text] [Related]  

  • 50. [Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?].
    Krzizok T
    Ophthalmologe; 2007 Sep; 104(9):759-62. PubMed ID: 17624534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S; Mathew N; Saper J; Jenkins S
    Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Safety and efficacy of botulinum toxin in hemifacial spasm].
    Mazlout H; Kamoun Gargouri H; Triki W; Kéfi S; Brour J; El Afrit MA; Chéour M; Kraiem A
    J Fr Ophtalmol; 2013 Mar; 36(3):242-6. PubMed ID: 23270989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Botulinum toxin injection for production of ptosis].
    Merté RL; Lanzl IM
    Ophthalmologe; 2007 Sep; 104(9):767-70. PubMed ID: 17846779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China.
    Huang XF; Wang KY; Liang ZH; Du RR; Zhou LN
    Eur Neurol; 2015; 73(5-6):337-41. PubMed ID: 25997849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Using botulinum toxin (Botox) for treatment of patients with postroke spasticity].
    Khat'kova SE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):87-90. PubMed ID: 19685598
    [No Abstract]   [Full Text] [Related]  

  • 56. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hyperfunctional lines of the face with botulinum toxin A.
    Binder WJ; Blitzer A; Brin MF
    Dermatol Surg; 1998 Nov; 24(11):1198-205. PubMed ID: 9834739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease).
    Freeman W; Wszolek Z
    Mov Disord; 2005 May; 20(5):644. PubMed ID: 15747361
    [No Abstract]   [Full Text] [Related]  

  • 59. Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction.
    Singer C; Papapetropoulos S; Vela L
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1608-9. PubMed ID: 16227568
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy.
    Kang BS; Bang MS; Jung SH
    Am J Phys Med Rehabil; 2007 Nov; 86(11):901-6. PubMed ID: 17873826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.